PMID- 36111814
OWN - NLM
STAT- MEDLINE
DCOM- 20221102
LR  - 20221207
IS  - 1470-8752 (Electronic)
IS  - 0300-5127 (Print)
IS  - 0300-5127 (Linking)
VI  - 50
IP  - 5
DP  - 2022 Oct 31
TI  - Protective HLA-B57: T cell and natural killer cell recognition in HIV infection.
PG  - 1329-1339
LID - 10.1042/BST20220244 [doi]
AB  - Understanding the basis of the immune determinants controlling disease outcome is 
      critical to provide better care to patients and could be exploited for 
      therapeutics and vaccine design. The discovery of the human immunodeficiency 
      virus (HIV) virus as the causing agent of acquired immunodeficiency syndrome 
      (AIDS) decades ago, led to a tremendous amount of research. Among the findings, 
      it was discovered that some rare HIV+ individuals, called HIV controllers (HICs), 
      had the ability to control the virus and keep a low viral load without the need 
      of treatment. This ability allows HICs to delay or avoid progression to AIDS. HIV 
      control is strongly associated with the expression of human leukocyte antigen 
      (HLA) alleles in HICs. From the HIV protective HLAs described, HLA-B57 is the 
      most frequent in HIC patients. HLA-B57 can present a large range of highly 
      conserved Gag-derived HIV peptides to CD8+ T cells and natural killer (NK) cells, 
      both the focus of this review. So far there are limited differences in the immune 
      response strength, magnitude, or receptor repertoire towards HIV epitopes that 
      could explain viral control in HICs. Interestingly, some studies revealed that 
      during early infection the large breadth of the immune response towards HIV 
      mutants in HLA-B57+ HIC patients, might in turn influence the disease outcome.
CI  - (c) 2022 The Author(s).
FAU - Lobos, Christian A
AU  - Lobos CA
AD  - Department of Biochemistry and Chemistry, La Trobe Institute for Molecular 
      Science, La Trobe University, Bundoora, VIC 3083, Australia.
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 
      3800, Australia.
FAU - Downing, Jonathan
AU  - Downing J
AD  - School of Biomedical Sciences, University of Western Australia, Nedlands, WA 
      6009, Australia.
AD  - Department of Clinical Immunology and PathWest, Fiona Stanley Hospital, Murdoch, 
      WA 6150, Australia.
FAU - D'Orsogna, Lloyd J
AU  - D'Orsogna LJ
AD  - School of Biomedical Sciences, University of Western Australia, Nedlands, WA 
      6009, Australia.
AD  - Department of Clinical Immunology and PathWest, Fiona Stanley Hospital, Murdoch, 
      WA 6150, Australia.
FAU - Chatzileontiadou, Demetra S M
AU  - Chatzileontiadou DSM
AD  - Department of Biochemistry and Chemistry, La Trobe Institute for Molecular 
      Science, La Trobe University, Bundoora, VIC 3083, Australia.
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 
      3800, Australia.
FAU - Gras, Stephanie
AU  - Gras S
AUID- ORCID: 0000-0001-7416-038X
AD  - Department of Biochemistry and Chemistry, La Trobe Institute for Molecular 
      Science, La Trobe University, Bundoora, VIC 3083, Australia.
AD  - Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 
      3800, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Biochem Soc Trans
JT  - Biochemical Society transactions
JID - 7506897
RN  - 0 (HLA-B57 antigen)
RN  - 0 (HLA-B Antigens)
SB  - IM
MH  - Humans
MH  - *HIV Infections
MH  - *HIV-1
MH  - *Acquired Immunodeficiency Syndrome
MH  - HLA-B Antigens/metabolism
MH  - CD8-Positive T-Lymphocytes/metabolism
MH  - Killer Cells, Natural/metabolism
PMC - PMC9704518
OTO - NOTNLM
OT  - CD8+ T cell
OT  - HIV
OT  - HLA-B57
OT  - immune response
OT  - natural killer cell
OT  - peptide presentation
COIS- The authors declare that there are no competing interests associated with the 
      manuscript.
EDAT- 2022/09/17 06:00
MHDA- 2022/11/03 06:00
PMCR- 2022/09/16
CRDT- 2022/09/16 08:12
PHST- 2022/06/30 00:00 [received]
PHST- 2022/08/28 00:00 [revised]
PHST- 2022/08/31 00:00 [accepted]
PHST- 2022/09/17 06:00 [pubmed]
PHST- 2022/11/03 06:00 [medline]
PHST- 2022/09/16 08:12 [entrez]
PHST- 2022/09/16 00:00 [pmc-release]
AID - 231820 [pii]
AID - BST-50-1329 [pii]
AID - 10.1042/BST20220244 [doi]
PST - ppublish
SO  - Biochem Soc Trans. 2022 Oct 31;50(5):1329-1339. doi: 10.1042/BST20220244.